Annual Report

Overview

The report presents Vigil Neuroscience as a clinical-stage biotechnology company advancing iluzanebart in the Phase 2 IGNITE trial for ALSP and VG-3927 in Phase 1 development. During 2023, IGNITE enrollment was completed with 20 patients, exceeding the initially planned 15, and the company launched ALSPAware to provide no-cost genetic testing and supportive counseling. The company reported 69 full-time employees as of February 29, 2024. It remained pre-revenue and reported a 2023 net loss of $82.638 million.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2023
Period: Ends 31 December 2023
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services